Clinical Trial: A Phase 3 Study of Daraxonrasib (RMC-6236) Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients with RAS Mutations

U.S., March 19 -- ClinicalTrials.gov registry received information related to the study (NCT06881784) titled 'A Phase 3 Study of Daraxonrasib (RMC-6236) Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients with RAS Mutations' on March 10.

Brief Summary: The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

Study Start Date: May 30

Study Type: INTERVENTIONAL

Condition: NSCLC (non-small Cell Lung Cancer) Non-Small Cell Lung Cancer NSCLC NSCLC (non-small Cell Lung Carcinoma) NSCLC (advanced Non-small Cell Lung Cancer)

Intervention: DRUG: daraxonrasib

oral tablets

DRUG: docetaxel

intravenous (IV) infusion

Recruitment Status: NOT_YET_RECRUITIN...